Best Peptide for Weight Loss: Comparing the Top Options in 2026

Weight loss peptides trace back to a simple discovery: the gut produces hormones that control hunger. In the 1980s, researchers identified GLP-1 (glucagon-like peptide-1) as a gut hormone that tells your brain you are full and tells your pancreas to release insulin. The idea of mimicking GLP-1 with a drug took decades to develop. Exenatide (Byetta) was the first GLP-1 agonist, approved for diabetes in 2005. It was a breakthrough, but the weight loss was modest, around 3 to 5 percent of body weight. It also required twice-daily injections. Liraglutide (Saxenda) came next, approved for weight management in 2014. It produced about 8 percent weight loss and only needed once-daily dosing. Better, but still not dramatic. Everything changed with semaglutide. Approved for diabetes as Ozempic in 2017 and for obesity as Wegovy in 2021, semaglutide hit 15 to 17 percent body weight loss in trials. Then tirzepatide arrived in 2022, a dual GLP-1/GIP agonist that pushed weight loss to 20 to 25 percent. These drugs turned obesity treatment upside down. Meanwhile, a separate line of research produced AOD-9604 and MOTS-c. AOD-9604 is a fragment of human growth hormone that targets fat metabolism without affecting blood sugar. MOTS-c is a mitochondrial-derived peptide that improves metabolic flexibility. Both are smaller players compared to GLP-1 drugs, but they have loyal followings.

The primary mechanism is GLP-1 receptor activation. When semaglutide binds to GLP-1 receptors in the brain, it dramatically reduces appetite and cravings. It also slows gastric emptying, so food stays in your stomach longer and you feel full sooner. In the pancreas, it improves insulin secretion in response to meals. Tirzepatide does everything semaglutide does, plus it hits GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors exist in the brain, fat tissue, and pancreas. The dual action appears to produce more weight loss and better metabolic outcomes than GLP-1 alone. Retatrutide takes it further. It is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Glucagon activation increases energy expenditure and fat oxidation. The result is weight loss that may exceed tirzepatide, with some trial data showing 24 percent or more body weight reduction. AOD-9604 works differently. It is a modified fragment of growth hormone (amino acids 177 to 191) that promotes lipolysis, the breakdown of fat. It does not affect insulin, does not suppress appetite, and has minimal side effects. The tradeoff is that it produces more modest fat loss on its own. MOTS-c is an exercise mimetic of sorts. It activates AMPK, a cellular energy sensor, and improves insulin sensitivity. It may help your body burn fat more efficiently, especially when combined with caloric deficit and exercise. Results are subtler than GLP-1 drugs.

Here are the real numbers from clinical trials and observational data. Semaglutide: 15 to 17 percent body weight loss over 68 weeks in the STEP trials. Participants lost an average of 33 to 35 pounds. The weight loss continues past 20 percent for some people at higher doses. Tirzepatide: 20 to 25 percent body weight loss in the SURMOUNT trials. At the highest dose (15mg), some participants lost over 50 pounds. The average weight loss was 48 pounds at the highest dose over 72 weeks. Retatrutide: Still in phase 3 trials as of 2026. Early data shows 24 percent weight loss at 12mg dose over 48 weeks. Some participants exceeded 30 percent. This drug has not been approved yet. AOD-9604: Clinical data is limited. A small Australian trial showed modest fat loss without significant side effects. Anecdotal reports suggest 2 to 4 percent body fat reduction over 12 weeks when combined with diet and exercise. It will not produce dramatic weight loss on its own. MOTS-c: Very limited human data. Animal studies show improved insulin sensitivity and protection against diet-induced obesity. Users report better energy, improved body composition, and enhanced exercise performance. Weight loss is secondary and modest.

GLP-1 peptides hit appetite hard, especially in the first few weeks. A user on r/Peptides wrote: “I took my first 0.25mg semaglutide shot on a Thursday evening. By Friday afternoon I realized I had not thought about food once. Normally I am snacking by 10am. That day I skipped lunch entirely and had a small dinner. It was not willpower. The desire to eat was just gone.“ Another user on r/Mounjaro shared: “Three months on tirzepatide. Down 28 pounds. The food noise is the biggest thing. That constant background chatter about what to eat next, when to eat, whether I should have a snack. It is just quiet now. I eat because I need to, not because my brain is screaming at me.“ Side effects are common in the first month. Nausea, occasional vomiting, constipation, and fatigue are the main complaints. Most people say these fade by week 4 to 6 as the body adjusts.

• Significant reduction in appetite and food cravings
• Feeling full after much smaller portions
• Steady weight loss of 1 to 3 pounds per week on GLP-1 drugs
• Improved blood sugar control and insulin sensitivity
• Reduced visceral fat (the dangerous fat around organs)
• Lower blood pressure in many users
• Reduced inflammation markers like CRP

For enhanced fat loss with semaglutide or tirzepatide: Add AOD-9604. The GLP-1 handles appetite and calorie intake. AOD-9604 may help mobilize stubborn fat stores, especially around the midsection. Dose 300mcg daily in the morning on an empty stomach. For metabolic support: Add MOTS-c. It works on a different pathway than GLP-1 drugs, targeting mitochondrial function and cellular energy. This pairing may help maintain energy levels during caloric restriction. Typical protocol is 5 to 10mg once or twice weekly. For muscle preservation: Add CJC-1295/Ipamorelin. Weight loss from GLP-1 drugs can include muscle loss. The GH peptides help preserve lean mass by maintaining growth hormone output. The improved sleep also helps with recovery and cortisol regulation. For gut health during weight loss: Add BPC-157. GLP-1 drugs slow gastric emptying, which can cause GI distress. BPC-157 protects the gut lining and may reduce some of these side effects. A user on r/Peptides noted: “Added BPC-157 to my semaglutide protocol. The nausea dropped by 80 percent and my digestion improved noticeably.“